JP2018150349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018150349A5 JP2018150349A5 JP2018098430A JP2018098430A JP2018150349A5 JP 2018150349 A5 JP2018150349 A5 JP 2018150349A5 JP 2018098430 A JP2018098430 A JP 2018098430A JP 2018098430 A JP2018098430 A JP 2018098430A JP 2018150349 A5 JP2018150349 A5 JP 2018150349A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- schizophrenia
- pharmaceutical composition
- disease
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 208000028017 Psychotic disease Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 201000000980 schizophrenia Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 208000024714 major depressive disease Diseases 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000030988 Schizoid Personality disease Diseases 0.000 claims 1
- 208000008039 Secondary Parkinson Disease Diseases 0.000 claims 1
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000024817 paranoid personality disease Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 0 O=C1NC(*=C*C2)=C2C=C1 Chemical compound O=C1NC(*=C*C2)=C2C=C1 0.000 description 2
- MWCHLFKQTXSQJV-UHFFFAOYSA-N CC1=NNCC1 Chemical compound CC1=NNCC1 MWCHLFKQTXSQJV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644947P | 2012-05-09 | 2012-05-09 | |
| US61/644,947 | 2012-05-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511676A Division JP6345651B2 (ja) | 2012-05-09 | 2013-05-09 | ヘテロアリール化合物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018150349A JP2018150349A (ja) | 2018-09-27 |
| JP2018150349A5 true JP2018150349A5 (enExample) | 2018-12-06 |
Family
ID=49551265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511676A Expired - Fee Related JP6345651B2 (ja) | 2012-05-09 | 2013-05-09 | ヘテロアリール化合物及びその使用方法 |
| JP2018098430A Pending JP2018150349A (ja) | 2012-05-09 | 2018-05-23 | ヘテロアリール化合物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511676A Expired - Fee Related JP6345651B2 (ja) | 2012-05-09 | 2013-05-09 | ヘテロアリール化合物及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9951088B2 (enExample) |
| EP (1) | EP2847193B1 (enExample) |
| JP (2) | JP6345651B2 (enExample) |
| AU (2) | AU2013259551B2 (enExample) |
| CA (1) | CA2872883A1 (enExample) |
| WO (1) | WO2013169964A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2882722B1 (en) | 2012-08-13 | 2016-07-27 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as gpr6 modulators |
| JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| WO2015123505A1 (en) | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyridopyrazines modulators of gpr6 |
| CN106831714B (zh) * | 2017-01-23 | 2019-05-17 | 南阳师范学院 | 一种四氢异喹啉化合物及其制备方法和用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1311492A (en) * | 1919-07-29 | Planouraph co | ||
| US1348388A (en) * | 1919-10-15 | 1920-08-03 | Harold P Bailey | Watch-bow |
| US3051709A (en) * | 1960-04-22 | 1962-08-28 | Us Vitamin Pharm Corp | Substitutedamino-3-(4-and 5-indanoxy)-propane-2-ols |
| GB903346A (en) * | 1960-05-31 | 1962-08-15 | Serono Ist Farm | A gonadotropic hormone devoid of antigen properties |
| NL278921A (enExample) * | 1961-05-26 | |||
| CA967965A (en) * | 1968-12-24 | 1975-05-20 | Hoffmann-La Roche Limited | Aromatic ethers and process for the manufacture thereof |
| BE756127A (fr) * | 1969-09-12 | 1971-03-15 | Hoechst Ag | Ethers heterocycliques et leur preparation |
| DE2337461A1 (de) * | 1973-07-24 | 1975-02-06 | Boehringer Mannheim Gmbh | Neue indolderivate und verfahren zu deren herstellung |
| JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2827566A1 (de) * | 1978-06-23 | 1980-01-10 | Boehringer Mannheim Gmbh | 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung |
| JPS5629581A (en) * | 1979-08-20 | 1981-03-24 | Otsuka Pharmaceut Co Ltd | 4-phenylpiperazinyl alkoxy anilide derivative |
| JPS55127371A (en) * | 1980-02-14 | 1980-10-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| PH17194A (en) * | 1980-03-06 | 1984-06-19 | Otsuka Pharma Co Ltd | Novel carbostyril derivatives,and pharmaceutical composition containing the same |
| US4803203A (en) * | 1986-11-05 | 1989-02-07 | Warner-Lambert Company | Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents |
| EP0424525B1 (en) * | 1987-12-11 | 1994-12-21 | Mitsui Petrochemical Industries, Ltd. | Novel amines and their use |
| FR2656609B1 (fr) * | 1989-12-28 | 1992-03-27 | Synthelabo | Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique. |
| FR2678272B1 (fr) * | 1991-06-27 | 1994-01-14 | Synthelabo | Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique. |
| GB2295387A (en) * | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| CN1249054C (zh) * | 2003-07-15 | 2006-04-05 | 重庆医药工业研究院有限责任公司 | 一种阿立哌唑的制备方法 |
| GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| AR046046A1 (es) * | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
| CA2574956A1 (en) * | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Heterocyclic acetophenone potentiators of metabotropic glutamate receptors |
| WO2006046131A1 (en) * | 2004-10-29 | 2006-05-04 | Pfizer Products Inc. | Tetralin histamine-3 receptor antagonists |
| WO2006072608A2 (en) * | 2005-01-03 | 2006-07-13 | Universitá Degli Studi Di Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| AU2006212765B2 (en) * | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| WO2006090272A1 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia |
| TW200643015A (en) * | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| EA201070077A1 (ru) * | 2007-06-29 | 2010-08-30 | Эмори Юниверсити | Антагонисты nmda-рецепторов с нейропротективным действием |
| WO2009025265A1 (ja) * | 2007-08-21 | 2009-02-26 | Shionogi & Co., Ltd. | ピペラジン誘導体 |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP2011520815A (ja) * | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| US8653069B2 (en) | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
| CN101712675B (zh) * | 2008-10-07 | 2013-07-03 | 江苏恒谊药业有限公司 | 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用 |
| US9156822B2 (en) * | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
-
2013
- 2013-05-09 JP JP2015511676A patent/JP6345651B2/ja not_active Expired - Fee Related
- 2013-05-09 WO PCT/US2013/040238 patent/WO2013169964A1/en not_active Ceased
- 2013-05-09 US US14/399,334 patent/US9951088B2/en active Active
- 2013-05-09 AU AU2013259551A patent/AU2013259551B2/en not_active Ceased
- 2013-05-09 EP EP13787303.0A patent/EP2847193B1/en active Active
- 2013-05-09 CA CA2872883A patent/CA2872883A1/en not_active Abandoned
-
2017
- 2017-10-10 AU AU2017245318A patent/AU2017245318A1/en not_active Abandoned
-
2018
- 2018-04-06 US US15/947,343 patent/US20190031685A1/en not_active Abandoned
- 2018-05-23 JP JP2018098430A patent/JP2018150349A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018150349A5 (enExample) | ||
| JP2018058890A5 (enExample) | ||
| JP2016508142A5 (enExample) | ||
| JP2013512926A5 (enExample) | ||
| JP2016155815A5 (enExample) | ||
| JP2018104454A5 (enExample) | ||
| JP2014505690A5 (enExample) | ||
| RU2502737C2 (ru) | Производные имидазопиридина или имидазопиримидина в качестве ингибиторов фосфодиэстеразы 10а | |
| JP2017503867A5 (enExample) | ||
| RU2010120528A (ru) | ИМИДАЗО[1, 2-А]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
| JOP20190144A1 (ar) | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز | |
| JP2015516432A5 (enExample) | ||
| JP2012526735A5 (enExample) | ||
| RU2018130547A (ru) | Производные пиразоло[1,5-а]пиразин-4-ила в качестве jак-ингибиторов | |
| HRP20190748T1 (hr) | Derivati policikličkog amida kao inhibitori cdk9 | |
| JP2019511460A5 (enExample) | ||
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| KR20170066417A (ko) | Pde1 억제제로서의 트리아졸로피라지논 | |
| NZ600008A (en) | Multicyclic compounds and methods of use thereof | |
| JOP20190143B1 (ar) | مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز | |
| JP2009538852A5 (enExample) | ||
| RU2011120816A (ru) | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов | |
| JP2014531458A5 (enExample) | ||
| ME02667B (me) | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini | |
| JP2018522869A5 (enExample) |